Marksans Pharma announced that its wholly owned subsidiary, Marksans Pharma Inc., has received final approval from the USFDA for its abbreviated new drug application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
The approved product is bioequivalent to the reference listed drug (RLD), Imodium A-D Tablets, 2 mg, marketed by Kenvue Brands LLC (NDA - 019860).
Loperamide Hydrochloride is an anti-diarrheal medication used to manage symptoms of acute and chronic diarrhea, strengthening Marksans Pharmas portfolio in the US generic pharmaceutical market.
Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.
The companys consolidated net profit rose 1.6% to Rs 98.25 crore on 12.2% jump in revenue from operations to Rs 720.41 crore in Q2 FY26 over Q2 FY25.
Shares of Marksans Pharma fell 1.46% to Rs 189.50 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app